Adage Capital Partners’s Syros Pharmaceuticals, Inc. Common Stock SYRS Stock Holding History

Adage Capital Partners’s Portfolio SYRS Stock Details SYRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-2,071,914	Closed	-$4.45M	–	978
2024 Q3	$4.45M	Hold	2,071,914	–	–	0.01%	727
2024 Q2	$10.7M	Hold	2,071,914	–	–	0.02%	590
2024 Q1	$11.1M	Hold	2,071,914	–	–	0.02%	580
2023 Q4	$16.1M	Buy	2,071,914 +1,350,000	+187%	+$4.62M	0.03%	488
2023 Q3	$2.85M	Hold	721,914	–	–	0.01%	720
2023 Q2	$2.27M	Hold	721,914	–	–	﹤0.01%	737
2023 Q1	$1.93M	Hold	721,914	–	–	﹤0.01%	767
2022 Q4	$2.59M	Hold	721,914	–	–	0.01%	800
2022 Q3	$4.65M	Buy	721,914 +531,914	+280%	+$4.32M	0.01%	788
2022 Q2	$1.83M	Hold	190,000	–	–	﹤0.01%	885
2022 Q1	$2.26M	Hold	190,000	–	–	﹤0.01%	893
2021 Q4	$6.19M	Buy	190,000 +10,000	+6%	+$405K	0.01%	792
2021 Q3	$8.05M	Buy	180,000 +94,770	+111%	+$4.63M	0.02%	757
2021 Q2	$4.64M	Buy	+85,230	New	+$5.04M	0.01%	834

Other funds holding SYRS

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OFM

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

Adage Capital Partners's SYRS Position: Q4 2024 in Review

Adage Capital Partners sold out of Syros Pharmaceuticals, Inc. Common Stock (SYRS) in Q4 2024, closing a stake of 2,071,914 shares — an estimated $4.45M sold.

Adage Capital Partners first reported a position in SYRS in Q2 2021 and held it in 14 quarters. The position peaked at $16.1M in Q4 2023. 44 funds tracked by Wall St. Rank hold SYRS as of Q4 2024.

Adage Capital Partners reported no remaining Syros Pharmaceuticals, Inc. Common Stock position as of Q4 2024 after selling out during the quarter.
Adage Capital Partners sold 2,071,914 Syros Pharmaceuticals, Inc. Common Stock shares in Q4 2024, an estimated $4.45M.
Adage Capital Partners first reported a position in Syros Pharmaceuticals, Inc. Common Stock in Q2 2021 and held it in 14 quarters.
Adage Capital Partners's Syros Pharmaceuticals, Inc. Common Stock position peaked at $16.1M in Q4 2023.
44 funds tracked by Wall St. Rank held Syros Pharmaceuticals, Inc. Common Stock as of Q4 2024.

Based on Adage Capital Partners's 13F filing for Q4 2024, filed 14 Feb 2025.